Approval · Notice of Compliance 22551 · 2019
TRULICITY: Notice of Compliance 22551
Issued August 15, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22551
- Date
- August 15, 2019
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product Monograph Update and New Indication: TRULICITY is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with sodium glucose co-transporter 2 inhibitor (SGLT2i) with metformin, when diet and excercise plus SGLT2i with or without metformin do not achieve adequate glycemic control.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRULICITY | Not yet assigned | — |
Medicinal ingredients
- DULAGLUTIDE 0.75 MG per 0.5ML
- DULAGLUTIDE 1.5 MG per 0.5ML
- DULAGLUTIDE 0.75 MG per PEN
- DULAGLUTIDE 1.5 MG per PEN